Results 171 to 180 of about 23,758 (203)

Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney disease

open access: yes
Promruk W   +9 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Epigenetic Regulation of Sost/sclerostin Expression

Current Molecular Biology Reports, 2017
Sclerostin, encoded by the gene Sost, is a regulatory glycoprotein produced by mature osteocytes in bone. Findings in animals and humans revealed that Sost/sclerostin deficiency results in increased bone density, and neutralizing antibodies to this protein are being investigated for treatment of postmenopausal osteoporosis.
Álvaro del Real   +2 more
openaire   +1 more source

SOST is a target gene for PTH in bone

Bone, 2005
Intermittent parathyroid hormone (PTH) application is an established pharmacological principle to stimulate bone formation. Yet, the molecular mechanisms underlying this bone anabolic action are not fully understood. Recently, SOST (sclerostin) was identified as a potent osteocyte expressed negative regulator of bone formation in vitro, in murine ...
Hansjoerg, Keller, Michaela, Kneissel
openaire   +2 more sources

Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene

Bone, 2016
SOST encodes sclerostin, an inhibitor of bone formation that antagonizes canonical Wnt signaling. Variations of SOST expression have an impact on bone mineral density (BMD) and bone strength. We hypothesized that genetic and epigenetic DNA modifications have an impact on SOST gene expression.
Lhaneche, Leila   +13 more
openaire   +5 more sources

Does osteocytic SOST suppression mediate PTH bone anabolism?

Trends in Endocrinology & Metabolism, 2010
Parathyroid hormone (PTH) has bone anabolic activity when administered intermittently, affecting cells of the osteoblastic lineage at various stages, yet much remains to be learned about precisely how PTH promotes osteoblastic bone formation. Recent discoveries revealed that PTH causes transcriptional suppression of the osteocyte marker gene SOST ...
Ina, Kramer   +3 more
openaire   +2 more sources

Novel SOST gene mutation in a sclerosteosis patient and her parents

Bone, 2013
Sclerosteosis (OMIM 269500) is a rare autosomal recessive condition characterized by increased bone density associated with syndactyly. It is linked to a genetic defect in the SOST gene coding for sclerostin. So far, six different loss-of-function mutations in SOST have been reported in patients with sclerosteosis.
Bhadada, Sanjay Kumar   +7 more
openaire   +3 more sources

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

Cytokine & Growth Factor Reviews, 2005
Sclerosteosis and Van Buchem disease are two closely related bone disorders characterized by progressive bone thickening due to increased bone formation. Sclerosteosis is associated with mutations in the SOST gene and Van Buchem disease with a 52 kb deletion downstream of the SOST gene that probably affects transcription of the gene.
Rutger L, van Bezooijen   +3 more
openaire   +2 more sources

The effects of SOST on implant osseointegration in ovariectomy osteoporotic mice

Archives of Oral Biology, 2017
Osteoporosis is a risk factor for implant fixation failure. The inhibition of sclerostin effectively improves bone formation and bone remodeling. Therefore, this study investigated whether SOST deficiency enhances the osseointegration of implants in a mouse model of osteoporosis induced by ovariectomy (OVX).Osteoporosis was induced in female C57BL/6 ...
Rui, Shu   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy